20/20 Biolabs, Inc.: Business Overview, Financials & Competitive Analysis
20/20 Biolabs, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage MCED player with pricing and convenience advantages, but scale and profitability risks limit near-term upside in a capital-intensive diagnostics market. 20/20 Biolabs operates in a high-growth MCED diagnostics space with differentiated at-home collection and cost positioning. However, as a micro-cap public company (19 employees reported), limited scale, narrow.
What is 20/20 Biolabs, Inc.'s industry? 20/20 Biolabs, Inc. (2020biolabs.com) operates in Diagnostic Laboratories. AskCyborg classifies 20/20 Biolabs, Inc. under Diagnostic Laboratories in its company registry.
20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company provides OneTest for Cancer, a multi-cancer early ...
Cyborg Score thesis
Early-stage MCED player with pricing and convenience advantages, but scale and profitability risks limit near-term upside in a...
Read the full analyst-debate transcript →Get the Latest 20/20 Biolabs, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report Free20/20 Biolabs, Inc. Overview
Pro stress-test →20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company provides OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory biomarkers. The company operates as a commercial-stage diagnostics firm leveraging machine learning to differentiate its offerings in the early disease detection market.
Strategic Profile
Pro stress-test →20/20 Biolabs pioneers affordable, accurate, actionable tests that can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. The company operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups, and was formerly known as 20/20 GeneSystems, Inc., changing its name in March 2025. Its competitive positioning emphasizes cost advantages—starting at under $200, versus just under $1,000 from leading competitors—and at-home sampling convenience.
Competitive Landscape
Pro stress-test →20/20 Biolabs competes in the multi-cancer early detection (MCED) diagnostics market against established players offering DNA-based tests, as well as emerging clinical laboratory and AI-driven diagnostics companies. The company differentiates on pricing (under $200 vs. ~$1,000), at-home sample collection, and proprietary machine learning algorithms applied to blood biomarkers. Key competitive pressures include larger, better-capitalized MCED developers, reimbursement uncertainty, and clinical validation demands.
Industry Context
20/20 Biolabs, Inc. operates in Diagnostic Laboratories.
Key facts
Founded: 2000 · Headquarters: Gaithersburg, Maryland · Employees: 19